Disease · MONDO_0005376

membranous glomerulonephritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. membranous glomerulonephritis. Diseases, record MONDO_0005376. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005376

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: membranous glomerulonephritis; Open Targets
Open Targets ID: MONDO_0005376; Open Targets
Other names: Heymann nephritis, glomerulonephritis, membranous, idiopathic membranous nephropathy, membranous Glomerulonephropathy, membranous nephropathy, nephropathy (idiopathic membranous); Open Targets
Disease Ontology: DOID:10976; Disease Ontology
MeSH: D015433; MeSH
NCI Thesaurus: C34645; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 8 of its 30 drugs, from ClinicalTrials.gov; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	9	9	7	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	8	8	5	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
MYCOPHENOLATE MOFETIL	CHEMBL1456	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	3	3	1	Drugs and targets
CHLORAMBUCIL	CHEMBL515	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TACROLIMUS	CHEMBL3989887	Small molecule	Phase 2/3	ClinicalTrials.gov	7	7	7	Drugs and targets
OBINUTUZUMAB	CHEMBL1743048	Antibody	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets16

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	5	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	3	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 2/3	https://conductscience.org/library/genes/2280	Drugs and targets
MC2R	Adrenocorticotropic hormone receptor	2	Melanocortin receptor 2 agonist	Phase 2	https://conductscience.org/library/genes/4158	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	1	Type-1 angiotensin II receptor antagonist	Unknown	https://conductscience.org/library/genes/185	Drugs and targets
ATP4A	Potassium-transporting ATPase	1	Potassium-transporting ATPase inhibitor	Unknown	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	1	Potassium-transporting ATPase inhibitor	Unknown	https://conductscience.org/library/genes/496	Drugs and targets
CD38	ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1	1	Lymphocyte differentiation antigen CD38 inhibitor	Phase 2	https://conductscience.org/library/genes/952	Drugs and targets
CFB	Complement factor B	1	Complement factor B inhibitor	Phase 2	https://conductscience.org/library/genes/629	Drugs and targets
IMPDH1	Inosine-5'-monophosphate dehydrogenase (IMPDH)	1	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3614	Drugs and targets

1 to 10 of 16

See all 16 targets

Trials48

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01180036	MEmbranous Nephropathy Trial Of Rituximab	Phase 2/3	130	2019-04-30	Idiopathic Membranous Nephropathy	CYCLOSPORINE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01282073	Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy	Phase 3	43	2025-08-27	Glomerulonephritis, Membranous	MYCOPHENOLATE MOFETIL, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT04154787	Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy	Phase 2	37	2024-07-05	Idiopathic Membranous Nephropathy	IPTACOPAN	Its record names the disease	ClinicalTrials.gov
NCT04145440	Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)	Phase 1/2	31	2024-12-24	Glomerulonephritis, Membranous, antiPLA2R Positive	FELZARTAMAB	Its record names the disease	ClinicalTrials.gov
NCT04745728	Different Immunosuppressive Treatment in iMN	Phase 3	200		Idiopathic Membranous Nephropathy	CYCLOPHOSPHAMIDE, PREDNISONE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02173106	A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy	Phase 2	180		Idiopathic Membranous Nephropathy, Proteinuria, Spontaneous Remission, Steroid Nephropathy, Cyclosporin Overdose	CYCLOSPORINE, METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT05862233	A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy	Phase 3	150		Primary Membranous Nephropathy	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT05696613	A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy	Phase 3	148		Primary Membranous Nephropathy	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03864250	Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy	Not applicable	124		Tacrolimus, Idiopathic Membranous Nephropathy, Clinical Trial	TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT03549663	Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)	Not applicable	108		Idiopathic Membranous Nephropathy	TACROLIMUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 48

See all 48 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Rituximab Treatment Arm vs Cyclosporine Treatment Arm: Remission Status	39 of 65	34 of 65	130	NCT01180036	Trial comparisons
Rituximab Treatment Arm vs Cyclosporine Treatment Arm: Remission Status	39 of 65	13 of 65	130	NCT01180036	Trial comparisons
Rituximab Treatment Arm vs Cyclosporine Treatment Arm: deaths from any cause	0 of 65	0 of 65	130	NCT01180036	Trial comparisons
Rituximab Treatment Arm vs Cyclosporine Treatment Arm: serious adverse events	11 of 65	20 of 65	130	NCT01180036	Trial comparisons
Mycophenolate Mofetil, Low Dose Steroid vs Cyclosporin, Low Dose Steroid: Percentage of Complete Remission	4 of 21	3 of 18	39	NCT01282073	Trial comparisons
Mycophenolate Mofetil, Low Dose Steroid vs Cyclosporin, Low Dose Steroid: deaths from any cause	0 of 21	0 of 18	39	NCT01282073	Trial comparisons
Mycophenolate Mofetil, Low Dose Steroid vs Cyclosporin, Low Dose Steroid: Percentage of Partial Remission	12 of 21	9 of 18	39	NCT01282073	Trial comparisons
Mycophenolate Mofetil, Low Dose Steroid vs Cyclosporin, Low Dose Steroid: serious adverse events	0 of 21	0 of 18	39	NCT01282073	Trial comparisons
Cohort 1 (Newly Diagnosed or Relapsed Participants) vs Cohort 2 (Refractory Participants): Number of Participants With AEs During the Follow-up Period	8 of 18	5 of 13	31	NCT04145440	Trial comparisons
Cohort 1 (Newly Diagnosed or Relapsed Participants) vs Cohort 2 (Refractory Participants): Number of Participants With Adverse Events	15 of 18	12 of 13	31	NCT04145440	Trial comparisons

Papers from its trials19

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25457107	RESULT	1	PubMed
40465397	DERIVED	2	PubMed
39513526	DERIVED	1	PubMed
36821613	DERIVED	1	PubMed
35224732	DERIVED	1	PubMed
34778952	DERIVED	13	PubMed
33649098	DERIVED	1	PubMed
32903623	DERIVED	1	PubMed
32231244	DERIVED	1	PubMed
31806605	DERIVED	1	PubMed

1 to 10 of 19

See all 19 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005376

GET https://conductscience.org/api/diseases/v1/MONDO_0005376/drugs?page=2

API reference For AI assistants